Based on the WuXi Biologics (Cayman) Inc stock forecast from 0 analysts, the average analyst target price for WuXi Biologics (Cayman) Inc is not available over the next 12 months. WuXi Biologics (Cayman) Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of WuXi Biologics (Cayman) Inc is Bullish , which is based on 7 positive signals and 3 negative signals. At the last closing, WuXi Biologics (Cayman) Inc’s stock price was USD 3.23. WuXi Biologics (Cayman) Inc’s stock price has changed by -3.00% over the past week, -6.81% over the past month and -72.72% over the last year.
No recent analyst target price found for WuXi Biologics (Cayman) Inc
No recent average analyst rating found for WuXi Biologics (Cayman) Inc
Company Overview WuXi Biologics (Cayman) Inc
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People's Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China. Read Less
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People's Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to ...Read More
Frequently Asked Questions About WuXi Biologics (Cayman) Inc (WXXWY) Stock
Stock Target Advisor's fundamental analysis for WuXi Biologics (Cayman) Inc's stock is Bullish .
Unfortunately we do not have enough data on WXXWY's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on WXXWY's stock to indicate what its average analyst target is.
WXXWY stock's Price/Earning ratio is 13.08.
Our analysis grades WXXWY stock's Price / Earning ratio at F. This means that WXXWY stock's Price/Earning ratio is above 44.99999999999999% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this WXXWY may be fairly valued for its sector
The last closing price of WXXWY's stock was USD 3.23.
The most recent market capitalization for WXXWY is USD 7.10B.
Unfortunately we do not have enough analyst data on WXXWY's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains WuXi Biologics (Cayman) Inc's stock.
As per our most recent records WuXi Biologics (Cayman) Inc has 12,397 Employees.
WuXi Biologics (Cayman) Inc's registered address is No. 108, Meiliang Road, Wuxi, China, 214092.
You can get more information about it from WuXi Biologics (Cayman) Inc's website at https://www.wuxibiologics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for WXXWY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
